Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
05/2003
05/21/2003CN1419559A Tricyclic protein kinase inhibitors
05/21/2003CN1419556A Pyrano [2,3-C] imidazo[-1,2-A] pyridine convenant au traitement de troubles gastrointestinal disorders
05/21/2003CN1419546A 4,5-dihydro-1h-pyrazole derivatives having cbi-antagonistic activity
05/21/2003CN1419545A 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
05/21/2003CN1419541A Pharmaceutically active pyrrolidine derivatives as BAX inhibitors
05/21/2003CN1419539A Amidino compound and salts thereof useful as nitric oxide synahase inhibitors
05/21/2003CN1419532A Novel fatty acid analogous
05/21/2003CN1419454A Use of lactic acid bacterium for the treatment of peritonitis
05/21/2003CN1419453A Pharmaceutical gel composition
05/21/2003CN1419445A Agent and binding agent for pharmaceutical formulations with improved storage stability
05/21/2003CN1418966A Resoldution method for racemic compound of nucleoside enantiomorph
05/21/2003CN1418964A Productive method of recombinant human liver regenerated enhanced factor and use in treating serious hepatopathy thereof
05/21/2003CN1418945A Wine containing astragalus base, ginseng and cordyceps sinensis and preparation process thereof
05/21/2003CN1418870A 3,4-dibidro-1H-anphthalene derivatives used as high selectivity inhibitor of cyclooxygenase-2
05/21/2003CN1418702A Guilingxianchao soft extract and preparation method thereof
05/21/2003CN1418701A Bushenshansong drink and preparation method thereof
05/21/2003CN1418693A Oral liquid medicine for treating stomach-pain, and its prepn. method
05/21/2003CN1418691A Health-care capsule for improving function of stomach and intestine
05/21/2003CN1418682A Medicine compositions for treating biliary calculus, and its prepn. method
05/21/2003CN1418679A Medicine compositions for treating hepatitis, and its prepn. method
05/21/2003CN1418677A Ointment for ulcer
05/21/2003CN1418673A Method for extracting coxtex mouten total glucoside for treating hepatitis
05/21/2003CN1418666A Chinese patent drug for treating hepatitis
05/21/2003CN1418665A Shalian regulating stomach-energy capsule (contg. Fructus and Fructus Forsythiae)
05/21/2003CN1418661A Traditional Chinese medicine prepn. for treating Hepatitis
05/21/2003CN1418659A Traditional Chinese medicine prepn. for eliminating mass and relieving dyspepsia
05/21/2003CN1418652A Traditional Chinese medicine granule contg. Radix Astragalus seu Hedysari, Herba Dendrobii, Frutus Crataegi; and its prepn. process
05/21/2003CN1418648A Medicine for treating hepatitis
05/21/2003CN1418637A Silicibinin-N-methylglucamine disperser for treating hepatitis, and its prepn. method
05/21/2003CN1418636A Compound prepn. contg. sophocarpidine and phosphatide, and its prepn. method
05/21/2003CN1418624A Alizapride oral disintegrant for treating emesis
05/21/2003CN1418620A Quick disintegrated tablet or oral cavity disintegrated tablet containing L-glutamic acid and azulene sodium sulfonate and making method thereof
05/21/2003CN1418582A Health-care tea
05/21/2003CN1418556A Health-care tea
05/21/2003CN1109108C Method for resolution of a racemic mixture of nucleoside enantioners
05/21/2003CN1109046C Induction of cytotoxic T-lymphocyte responses
05/21/2003CN1109033C 8-subtituted-9H-1,3-dioxolo/4,5-h/2, 2/henzodiazepine derivatives, as Ampa/kainate receptor inhibitors
05/21/2003CN1108813C Detoxicating stasis-dispersing inflammation-relieving antalgic and refreshing medicine and its preparing process
05/21/2003CN1108812C Helath care tea and preparation method thereof
05/21/2003CN1108799C Use of K-252A derivative for treatment of peripheral or central nerve disorders, and cytokine overproduction
05/20/2003US6566554 Including amino benzothiophenones; useful for treatment of inflammatory diseases in which the production of cytokines is involved in the pathogenesis
05/20/2003US6566506 Useful in extending the in vivo circulating life of biologically active materials
05/20/2003US6566405 Drugs, cosmetics or dietary supplements; immunomodulation, antiallergens (IgE mediated allergies, e.g., asthma, rhinitis, eczema); anaphylaxis; autoimmune disorders, e.g., Crohn's disease, antiarthritic and ulcer agents; analgesics
05/20/2003US6566398 Method for treatment of external secretion disorders
05/20/2003US6566387 For therapy of psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock
05/20/2003US6566377 Have utility as, inter alia, hypoglycemic, and anti-obesity agents.
05/20/2003US6566368 Aministering apomorphine or a pharmaceutically acceptable acid addition salt thereof intranasally and in an amount sufficient to induce an erection adequate for vaginal penetration but less than the amount that induces substantial nausea
05/20/2003US6566357 Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
05/20/2003US6566356 3-amido or 3-sulfonylamino azetidine compounds and their preparation; high affinity for cannabinoid receptor CB1 type, useful in treating central nervous system, immune, gastrointestinal or cardiovascular disorders, drug abuse
05/20/2003US6566354 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
05/20/2003US6566352 Administering alpha -hydroxy-2-methylene-19-nor-pregnacalciferol compound for therapy of psoriasis
05/20/2003US6566350 Minocycline-containing compositions
05/20/2003US6566338 Administering caspase inhibitor for therapy of oral mucositis, gastrointestinal mucositis, bladder mucositis or proctitis resulting from chemotherapy or radiation therapy of cancer in an animal
05/20/2003US6566080 Assay for and uses of peptide hormone receptor agonists
05/20/2003US6565880 Antiinflammatory agents
05/20/2003US6565831 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
05/15/2003WO2003040726A2 Screening for hepatitis c virus entry inhibitors
05/15/2003WO2003040371A1 Novel g protein-coupled receptor protein and dna thereof
05/15/2003WO2003040358A1 Somatic cell derived embryonic stem cells and its differentiated cells
05/15/2003WO2003040351A1 A novel non-antibiotic strategy against ogip infections based on an activated cereal product or ferric quinate
05/15/2003WO2003040329A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003WO2003040310A2 Novel epidermal growth factor protein and gene, and methods of use therefor
05/15/2003WO2003040296A2 Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis
05/15/2003WO2003040188A1 Antibody stimulating il-1ra production
05/15/2003WO2003040131A1 Aminopyrimidines and pyridines
05/15/2003WO2003040127A1 Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
05/15/2003WO2003040115A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003WO2003040106A1 Preparation and use of substituted imidazoles
05/15/2003WO2003040099A1 Preparation of benzosuberonylpiperidine compounds
05/15/2003WO2003040098A1 Novel metalloproteinase inhibitors
05/15/2003WO2003040084A1 Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists
05/15/2003WO2003040080A2 Lipoxin a4 analogs
05/15/2003WO2003039677A2 Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
05/15/2003WO2003039590A1 Pharmaceutical composition comprising factor vii polypeptides and aprotinin polypeptides
05/15/2003WO2003039580A1 Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
05/15/2003WO2003039574A1 Endophilin homologous proteins involved in the regulation of energy homeostasis
05/15/2003WO2003039561A1 Pharmaceutical composition
05/15/2003WO2003039548A1 Hydrazono-malonitriles
05/15/2003WO2003039544A1 Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
05/15/2003WO2003039541A1 4-[3,5-bis-(2-hydroxy-phenyl)-[1,2,4]triazol-1-yl]-benzoic acid derivatives for treating an excess of metal in the body
05/15/2003WO2003039523A2 OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
05/15/2003WO2003039517A1 Process for preparing quick dissolving, high loading ribavirin compositions
05/15/2003WO2003039504A1 Solid oral compositions
05/15/2003WO2003039488A2 A method for treating inflammatory bowel disease
05/15/2003WO2003039473A2 Method for treating or preventing inflammatory diseases
05/15/2003WO2003039472A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003WO2003039465A2 Treating canker sores with patches to speed healing and relieve pain
05/15/2003WO2003039452A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003WO2003039451A2 Thiazole pyridazinones as adenosine antagonists
05/15/2003WO2003039446A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
05/15/2003WO2003039434A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
05/15/2003WO2003039260A2 Probiotic compositions
05/15/2003WO2003039231A2 Compounds and methods for treating transplant rejection
05/15/2003WO2003039225A2 Antigen arrays comprising rankl for treatment of bone disease
05/15/2003WO2002097032A3 Proteins associated with cell growth, differentiation, and death
05/15/2003WO2002083926A3 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002055108A9 Targeted modification of intracellular compounds
05/15/2003WO2002040480A3 Crf receptor antagonists and methods relating thereto
05/15/2003WO2002029031A3 Isoprenoid-dependent ras anchorage (idra) proteins
1 ... 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 ... 1258